This has reference to the press release issued by the Company today titled Strides Strengthens its Africa Business with the Acquisition of Multiple Generic Brands from Sandoz .In this regard, please find enclosed herewith disclosure under Regulation 30 of SEBI Listing Regulations.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 2.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science's step-down subsidiary SPIAG (Switzerland) has signed definitive agreements with Sandoz AG to acquire and in-license branded generic products across the Sub-Saharan Africa region, covering Western Sahara, Ghana, Nigeria, and Kenya. The portfolio spans anti-infective, cardiovascular, and dermatology segments, with several brands individually generating over USD 1 million in annual sales. Upfront consideration is USD 12 million, payable at closing, plus variable royalty payments on net sales of distribution products. The deal is expected to close by end of Q2 FY27 (September 30, 2026) and would position Strides among the top 5 pharma companies in the SSA region and top 2 in its represented markets. A corporate guarantee for the USD 12 million upfront and royalty obligations has been provided by another step-down subsidiary, SPG Singapore.
This acquisition expands Strides' Africa footprint and adds revenue-generating brands, likely to be viewed positively by the market as it strengthens the company's regional leadership. The deal size of USD 12 million upfront is relatively modest for the listed entity, with no material financial impact on the parent company, though contingent liability arises at the SPG level.